Mobile App Boosts Viral Suppression in HIV+ Men Who Apply Stimulants

Denver, Colorado – A fresh mobile application is showing promise in improving viral suppression among men living with HIV who also use crystal methamphetamine. Data presented at the Conference on Retroviruses and Opportunistic Infections (CROI) 2026 revealed that participants using the app experienced a 58% reduction in the odds of having a detectable viral load after six months, compared to a control group.

Addressing a Critical Need

Men who use stimulants often face challenges adhering to consistent antiretroviral therapy (ART), leading to higher rates of viral non-suppression and an increased risk of HIV transmission. This innovative approach, leveraging technology and behavioral interventions, aims to bridge that gap and improve health outcomes for this vulnerable population. The research highlights the growing recognition that effective HIV care must address co-occurring substance use.

The START Study: A Multi-Component Intervention

The findings stem from the Supporting Treatment Adherence for Resilience and Thriving (START) study, a fully remote randomized controlled trial. Professor Adam Carrico of Florida International University, a principal investigator on the START study, presented the results at CROI 2026. Professor Sabina Hirshfield from SUNY Downstate Health Sciences University, New York City, also a principal investigator, provided further details on the intervention.

“we locate that the START mHealth application achieved clinically meaningful – albeit short term – reductions in viral load,” stated Professor Carrico. The START study utilizes a multi-component approach, integrating technology with evidence-based interventions.

The Importance of Comprehensive Approaches

Researchers emphasize the need for comprehensive approaches that integrate substance use treatment options, such as remote contingency management. Injection drug use, including methamphetamine, remains a significant driver of the HIV epidemic in the US and globally. Chemsex, the pairing of meth use with sexual activity, is common among gay and bisexual men, and ongoing stimulant use can negatively impact ART adherence, leading to detectable viral loads.

Understanding Viral Load and Control Groups

A detectable viral load indicates that HIV is replicating in the body. If a person taking HIV treatment has a detectable viral load, it means the treatment isn’t working effectively and there may still be a risk of HIV transmission to sexual partners. A control group in a clinical trial receives standard treatment or no treatment, allowing researchers to compare outcomes with those receiving the experimental treatment.

Further information about the START study can be found on ClinicalTrials.gov.